A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia

Trial Profile

A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Donepezil/solifenacin (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Chase Pharmaceuticals
  • Most Recent Events

    • 27 Jul 2016 According to a Chase Pharmaceuticals media release, the data was presented at the 2016 Alzheimers Association Conference (AAIC).
    • 27 Jul 2016 Results published in the Chase Pharmaceuticals media release.
    • 25 Jul 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top